REGN•benzinga•
Regeneron Pharmaceuticals Announced 63% Combined Pathologic Response Rate for Neoadjuvant Libtayo Monotherapy in Stage II to IV Resectable CSCC Per Primary Analysis of a Confirmatory Phase 2 Trial; Data Presented at ESMO
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 12, 2022 by benzinga